Selank Research Guide: Anxiolytic Mechanism, Nootropic Properties & Studies

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with the sequence Pro-Gly-Pro to enhance metabolic stability and CNS bioavailability. Selank has been registered as a pharmaceutical drug in Russia for the treatment of generalized anxiety disorder and neurasthenia, and has accumulated a substantial body of preclinical and clinical research covering anxiolytic, nootropic, and immunomodulatory mechanisms.

For research use only. Not intended for human or veterinary use.

Background: Tuftsin and Peptide-Based Anxiolytics

Tuftsin is an endogenous tetrapeptide produced by enzymatic cleavage of IgG in the spleen, known primarily as an immune activator but also studied for neuroactive properties. Selank’s design extended tuftsin with a Pro-Gly-Pro tripeptide tail derived from another endogenous neuropeptide, significantly increasing plasma half-life while retaining and amplifying tuftsin’s CNS activity. Unlike benzodiazepine anxiolytics, which act through GABA-A receptor potentiation and carry significant risks of dependence, cognitive impairment, and withdrawal, Selank’s proposed mechanisms involve modulation of BDNF expression, serotonin metabolism, and enkephalin systems, a profile associated with anxiolysis without sedation or dependence liability in research models.

Structure and Pharmacokinetics

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids)
• Molecular weight: 751.9 Da
• Administration routes studied: Intranasal (most common in clinical use, direct CNS delivery via olfactory pathway), subcutaneous, intravenous
• Half-life: Approximately 2–3 minutes in plasma; intranasal administration produces longer CNS exposure via olfactory-brain transport, circumventing rapid peripheral degradation
• Regulatory status: Registered pharmaceutical drug in Russia (anxiolytic/nootropic indication)

Mechanism of Action

BDNF Upregulation

Brain-derived neurotrophic factor (BDNF) is a neurotrophin critical for neuronal survival, synaptic plasticity, and mood regulation. Reduced BDNF expression is consistently documented in anxiety disorders and depression and is a therapeutic target of multiple antidepressant drug classes. Semenova et al. (2010) demonstrated that Selank administration significantly increased BDNF expression in rat frontal cortex and hippocampus, providing a neurotrophic mechanism for its anxiolytic and cognitive effects. This BDNF-upregulating property is shared with exercise and certain antidepressants, and positions Selank within an increasingly well-characterized neurobiological framework.

Serotonin Metabolism Modulation

Research has documented Selank’s effects on serotonergic neurotransmission. Zozulya et al. (2001) showed that Selank modulated the activity of enzymes responsible for serotonin catabolism, specifically monoamine oxidase A (MAO-A), leading to increased serotonin availability in CNS regions associated with anxiety and mood. This serotonin-stabilizing mechanism, without direct receptor agonism, may contribute to Selank’s anxiolytic profile without the receptor-level side effects of direct serotonergic drugs.

Enkephalin System Effects

Selank has been shown to modulate enkephalin-degrading enzyme activity, increasing the bioavailability of endogenous enkephalins (endogenous opioid peptides involved in stress response regulation and anxiolysis). This enkephalin-sparing mechanism provides an additional anxiolytic pathway distinct from GABA, serotonin, or noradrenergic systems, potentially explaining why Selank’s anxiolytic profile in research models does not include the sedation, muscle relaxation, or memory impairment characteristic of GABAergic anxiolytics.

Immunomodulatory Effects

As a tuftsin analog, Selank retains immunomodulatory properties from its parent peptide. Research has documented effects on T cell function, natural killer cell activity, interferon expression, and interleukin balance, consistent with tuftsin’s known immune-activating profile. This dual CNS/immune activity profile is of interest in research examining the brain-immune axis and neuroinflammation in anxiety and stress disorders.

Key Research Findings

Anxiolytic Effects Without Sedation

Semenova et al. (2009) examined Selank’s anxiolytic properties in multiple rodent anxiety models (elevated plus maze, light-dark box, open field test), documenting significant anxiety reduction comparable to benzodiazepine reference compounds at equivalent anti-anxiety doses. Crucially, Selank did not produce sedation, motor impairment, or muscle relaxation, effects that uniformly accompany benzodiazepine anxiolysis and limit clinical utility. This separation of anxiolysis from sedation in animal models is a primary pharmacological argument for Selank’s research interest as a potential non-sedating anxiolytic tool compound.

Clinical Anxiety Research

Generalized anxiety disorder (GAD) clinical trials with Selank conducted in Russia demonstrated significant reductions in Hamilton Anxiety Scale (HAM-A) scores versus placebo, with an onset of anxiolytic effect within the first week of treatment. Compared to benzodiazepine-treated control groups, Selank patients showed comparable anxiety reduction with superior cognitive function maintenance, absence of sedation, and no withdrawal symptoms on discontinuation, a safety and tolerability profile that has sustained research interest despite the compound’s limited availability outside Russia.

Nootropic and Cognitive Effects

Beyond anxiolysis, Selank has been studied for nootropic properties, specifically effects on memory consolidation, learning, and cognitive performance under stress. Animal models have documented improved performance in memory tasks following Selank administration, with effects attributed to BDNF-mediated synaptic plasticity enhancement in the hippocampus. The stress-inoculating cognitive effects, maintaining or improving cognitive performance in stressful conditions, have made Selank of interest in neuroenhancement research separate from its anxiolytic indication.

Antiviral Research

Consistent with tuftsin’s immune-activating heritage, Selank has been examined in antiviral contexts. Studies have reported enhanced interferon expression and NK cell activity in Selank-treated subjects during influenza challenge models. While not an antiviral drug, Selank’s immune-modulatory properties, combined with its CNS activity, have made it a subject of interest for research into psychoneuroimmunology and the bidirectional relationship between stress, immunity, and infection susceptibility.

Reconstitution Protocol

Selank for research purposes is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water.

• Inject bacteriostatic water slowly along the inner wall of the vial, do not direct the stream onto the lyophilized powder
• Gently swirl until fully dissolved; solution should be clear and colorless
• Common research concentration: 0.15 mg/mL (matching the registered nasal spray concentration) or higher concentrations for parenteral research models
• Refrigerate reconstituted solution at 2–8°C; stable approximately 4 weeks; protect from light
• Do not freeze reconstituted solution

References

• Semenova, T. P., Kozlovskii, I. I., Zakharova, N. M., & Kozlovskii, V. I. (2010). Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Doklady Biological Sciences, 430(1), 33–35.
• Zozulya, A. A., Nezavibatko, V. N., Semenova, T. P., Kolobov, V. V., Zarubina, I. V., Gabaeva, M. V., … & Mikheeva, I. G. (2001). Synthesis and neuropsychotropic activity of a heptapeptide analog of tuftsin. Pharmaceutical Chemistry Journal, 35(3), 1–4.
• Kozlovskaya, M. M., Semenova, T. P., Kozlovskii, I. I., & Andreeva, L. A. (2012). Pharmacology of Selank, results and new directions. Pharmaceutical Chemistry Journal, 46(8), 462–464.
• Uchakina, O. N., Uchakin, P. N., Miasoedov, N. F., Andreeva, L. A., Shcherbenko, V. E., Mezentseva, M. V., … & Ershov, F. I. (2008). Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(5), 71–75.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.

Research-Grade Selank Available

Exceed Enhancement offers research-grade Selank for qualified research applications. View product specifications and ordering information →